Literature DB >> 24688120

New therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis.

Chiung-Kuei Huang1, Haiyan Pang, Lin Wang, Yuanjie Niu, Jie Luo, Eugene Chang, Janet D Sparks, Soo Ok Lee, Chawnshang Chang.   

Abstract

The male sex has a higher risk to develop coronary artery diseases, including atherosclerosis. The androgen receptor (AR) is expressed in several atherosclerosis-associated cell types, including monocytes/macrophages, endothelial cells (ECs), and smooth muscle cells (SMCs), but its pathophysiological role in each cell type during the development of atherosclerotic lesions remains unclear. Using the Cre-loxP system, we selectively knocked out AR in these 3 cell types and the resultant AR knockout (ARKO) mice, monocyte/macrophage ARKO, EC-ARKO, and SMC-ARKO, were then crossed with the low-density lipoprotein receptor (LDLR) deficient (LDLR(-/-)) mice to develop monocyte/macrophage ARKO-LDLR(-/-), EC-ARKO-LDLR(-/-), and SMC-ARKO-LDLR(-/-) mice for the study of atherosclerosis. The results showed that the monocyte/macrophage ARKO-LDLR(-/-) mice had reduced atherosclerosis compared with the wild-type-LDLR(-/-) control mice. However, no significant difference was detected in EC-ARKO-LDLR(-/-) and SMC-ARKO-LDLR(-/-) mice compared with wild-type-LDLR(-/-) mice, suggesting that the AR in monocytes/macrophages, and not in ECs and SMCs, plays a major role to promote atherosclerosis. Molecular mechanism dissection suggested that AR in monocytes/macrophages upregulated the tumor necrosis factor-α, integrin β2, and lectin-type oxidized LDL receptor 1 molecules that are involved in 3 major inflammation-related processes in atherosclerosis, including monocytes/macrophages migration and adhesion to human umbilical vein ECs, and subsequent foam cell formation. Targeting AR via the AR degradation enhancer, ASC-J9, in wild-type-LDLR(-/-) mice showed similar effects as seen in monocyte/macrophage ARKO-LDLR(-/-) mice with little influence on lipid profile. In conclusion, the AR in monocytes/macrophages plays key roles in atherosclerosis and targeting AR with ASC-J9 may represent a new potential therapeutic approach to battle atherosclerosis.

Entities:  

Keywords:  androgen; atherosclerosis; macrophages; receptors, androgen

Mesh:

Substances:

Year:  2014        PMID: 24688120      PMCID: PMC4080890          DOI: 10.1161/HYPERTENSIONAHA.113.02804

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  30 in total

Review 1.  The decline of androgen levels in elderly men and its clinical and therapeutic implications.

Authors:  Jean M Kaufman; Alex Vermeulen
Journal:  Endocr Rev       Date:  2005-05-18       Impact factor: 19.871

2.  Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels.

Authors:  Ruud Out; Menno Hoekstra; Kim Habets; Illiana Meurs; Vivian de Waard; Reeni B Hildebrand; Yanan Wang; Giovanna Chimini; Johan Kuiper; Theo J C Van Berkel; Miranda Van Eck
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-11-15       Impact factor: 8.311

3.  Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression.

Authors:  Jiann-Jyh Lai; Kuo-Pao Lai; Kuang-Hsiang Chuang; Philip Chang; I-Chen Yu; Wen-Jye Lin; Chawnshang Chang
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

Review 4.  Epidemiology: testosterone and the metabolic syndrome.

Authors:  J Svartberg
Journal:  Int J Impot Res       Date:  2006-07-20       Impact factor: 2.896

5.  ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.

Authors:  Zhiming Yang; Yu-Jia Chang; I-Chen Yu; Shuyuan Yeh; Cheng-Chia Wu; Hiroshi Miyamoto; Diane E Merry; Gen Sobue; Lu-Min Chen; Shu-Shi Chang; Chawnshang Chang
Journal:  Nat Med       Date:  2007-03-04       Impact factor: 53.440

6.  Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor.

Authors:  Hung-Yun Lin; Qingquan Xu; Shuyuan Yeh; Ruey-Sheng Wang; Janet D Sparks; Chawnshang Chang
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

Review 7.  Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.

Authors:  Sadeka Shahani; Milena Braga-Basaria; Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

8.  An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome.

Authors:  Farid Saad; Louis Gooren; Ahmad Haider; Aksam Yassin
Journal:  Arch Androl       Date:  2007 Nov-Dec

9.  Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue.

Authors:  I-Chen Yu; Hung-Yun Lin; Ning-Chun Liu; Ruey-Shen Wang; Janet D Sparks; Shuyuan Yeh; Chawnshang Chang
Journal:  Endocrinology       Date:  2008-02-14       Impact factor: 4.736

10.  A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.

Authors:  Farid Saad; Louis J Gooren; Ahmad Haider; Aksam Yassin
Journal:  J Androl       Date:  2007-10-03
View more
  18 in total

1.  Limited Macrophage Positional Dynamics in Progressing or Regressing Murine Atherosclerotic Plaques-Brief Report.

Authors:  Jesse W Williams; Catherine Martel; Stephane Potteaux; Ekaterina Esaulova; Molly A Ingersoll; Andrew Elvington; Brian T Saunders; Li-Hao Huang; Andreas J Habenicht; Bernd H Zinselmeyer; Gwendalyn J Randolph
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

2.  Androgen receptor promotes abdominal aortic aneurysm development via modulating inflammatory interleukin-1α and transforming growth factor-β1 expression.

Authors:  Chiung-Kuei Huang; Jie Luo; Kuo-Pao Lai; Ronghao Wang; Haiyan Pang; Eugene Chang; Chen Yan; Janet Sparks; Soo Ok Lee; Joshua Cho; Chawnshang Chang
Journal:  Hypertension       Date:  2015-10       Impact factor: 10.190

Review 3.  Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?

Authors:  Piotr Zareba; Wilhelmina Duivenvoorden; Darryl P Leong; Jehonathan H Pinthus
Journal:  Ther Adv Urol       Date:  2015-11-30

4.  Androgen receptors and experimental bone loss - an in vivo and in vitro study.

Authors:  Joao Paulo Steffens; Leila Santana Coimbra; Carlos Rossa; Alpdogan Kantarci; Thomas E Van Dyke; Luis Carlos Spolidorio
Journal:  Bone       Date:  2015-10-09       Impact factor: 4.398

Review 5.  Androgen receptor (AR) in cardiovascular diseases.

Authors:  Chiung-Kuei Huang; Soo Ok Lee; Eugene Chang; Haiyan Pang; Chawnshang Chang
Journal:  J Endocrinol       Date:  2016-01-14       Impact factor: 4.286

Review 6.  Nuclear receptors in vascular biology.

Authors:  David Bishop-Bailey
Journal:  Curr Atheroscler Rep       Date:  2015-05       Impact factor: 5.113

7.  Androgen receptor deficiency in monocytes/macrophages does not alter adiposity or glucose homeostasis in male mice.

Authors:  Katya B Rubinow; Barbara Houston; Shari Wang; Leela Goodspeed; Kayoko Ogimoto; Gregory J Morton; Christopher McCarty; Robert E Braun; Stephanie T Page
Journal:  Asian J Androl       Date:  2018 May-Jun       Impact factor: 3.285

8.  Testosterone Protects Against Atherosclerosis in Male Mice by Targeting Thymic Epithelial Cells-Brief Report.

Authors:  Anna S Wilhelmson; Marta Lantero Rodriguez; Elin Svedlund Eriksson; Inger Johansson; Per Fogelstrand; Alexandra Stubelius; Susanne Lindgren; Johan B Fagman; Göran K Hansson; Hans Carlsten; Mikael C I Karlsson; Olov Ekwall; Åsa Tivesten
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-05-31       Impact factor: 8.311

Review 9.  Sex effects in pyelonephritis.

Authors:  Clayton D Albracht; Teri N Hreha; David A Hunstad
Journal:  Pediatr Nephrol       Date:  2020-02-10       Impact factor: 3.714

10.  Atheroprotective effects of statins in patients with unstable angina by regulating the blood-borne microRNA network.

Authors:  Sufang Li; Chengfu Cao; Hong Chen; Junxian Song; Chongyou Lee; Jing Zhang; Feng Zhang; Qiang Geng; Zheng Li; Jingjin Li
Journal:  Mol Med Rep       Date:  2017-05-24       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.